Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme

NCT00562419 is registered in ClinicalTrials.gov with Adnexus, A Bristol-Myers Squibb R&D Company as lead sponsor.

NCT NCT00562419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00562419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2007
Completion date
December 31, 2011
Enrollment
72 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, recurrent glioblastoma multiforme